Core Viewpoint - Huge Dental Limited (Shandong Hujie Dental Medical Group Co., Ltd.) is making its third attempt to go public on the Hong Kong Stock Exchange after facing multiple challenges in its previous IPO attempts in China [1][2]. Group 1: Company Background and IPO Journey - Established in November 2006, Huge Dental is the largest manufacturer of dental impression materials in China and one of the largest manufacturers of clinical dental materials [5]. - The company was listed on the New Third Board in 2015 but delisted in 2017, subsequently attempting to IPO on the A-share market multiple times from 2017 to 2023, all of which ended unsuccessfully due to various regulatory concerns [5]. - Key issues highlighted during the A-share attempts included significant shareholding irregularities and financial control problems, which were major factors in the failed IPOs [5]. Group 2: Financial Performance and Challenges - The company's revenue growth has stagnated, with projected revenues of 3.58 billion, 3.99 billion, and 4.00 billion yuan for 2023, 2024, and 2025 respectively, showing a decline in growth rate from 27.86% to 11.45% and then to just 0.25% [10]. - Net profit has also been on a downward trend, with figures of 0.88 billion, 0.77 billion, and 0.48 billion yuan for the same years, indicating a significant drop of 37.7% in 2025 [10]. - The company's high operating expenses are concerning, with sales, administrative, and R&D costs accounting for 42.4% of revenue in the first half of 2025, severely impacting profitability [11]. Group 3: Market Position and Competitive Landscape - Huge Dental's business is heavily concentrated in traditional dental materials, with 97.8% of revenue coming from clinical and technician products, while digital products contribute only 0.2% [11]. - The company faces intense competition in high-growth areas like invisible orthodontics, where its market share remains below 2%, despite price reductions [11]. - The average price of its synthetic resin teeth has remained stable at 0.9 yuan per piece, indicating a price-sensitive market [11]. Group 4: Future Growth Strategies - The company aims to expand production capacity and pursue international markets as part of its growth strategy, with plans to enhance production lines in Rizhao, Shandong, and invest in digital technology [12]. - However, the overseas revenue share has decreased from 46.95% in 2021 to 23.85% in 2024, raising questions about the effectiveness of its international expansion efforts [12].

Core Insights - The company aims to break the foreign monopoly in the dental clinical and technician product market, which has been dominated by foreign brands holding approximately 70% market share. The company has developed products that meet international standards and is expected to rank first in sales revenue by 2024 [1][3]. Business Model and Sales Network - The company has established a strong sales network domestically through a wide range of distributors and dental technician networks, while internationally, its products are certified in over 60 countries, with key markets including Europe, the USA, and Southeast Asia [2]. Revenue and Profit Trends - The company experienced robust revenue growth from 2022 to 2024, with revenue increasing from 280 million yuan in 2022 to 358 million yuan in 2023 (up 27.7%), and further to 399 million yuan in 2024 (up 11.7%) [3][4]. - The pre-tax profit also showed a growth trend, rising from 77 million yuan in 2022 to 106 million yuan in 2023 (up 37.8%), and further to 111 million yuan in 2024 (up 4.7%) [5][6]. Gross Margin Analysis - The overall gross margin remained relatively stable from 2022 to 2024, with figures of 47.6% in 2022, 49.4% in 2023, and 49.7% in 2024. However, there are differences in gross margins across various product categories [7][8]. Net Margin Insights - The net profit margin followed a similar growth trend, with net margins of approximately 27.4% in 2022, 29.6% in 2023, and a slight decrease to 27.7% in 2024, indicating potential impacts from cost control and market competition [9][10]. Revenue Composition - Key products such as elastic impression materials, composite resin teeth, temporary crown and bridge resin blocks, and clear aligners contributed significantly to revenue, with elastic impression materials accounting for nearly 40% of total revenue during the reporting period [11][12]. Competitive Landscape - The company holds a leading position in the market for certain products, ranking first in China for elastic impression materials and composite resin teeth by 2024. However, the overall market remains highly competitive, necessitating continuous improvement in R&D, production, and sales capabilities [16][17]. Customer Concentration Risks - The company faces significant revenue impacts from fluctuations in orders from American clients, highlighting a high dependency on certain customers. There is a need to diversify the customer base to mitigate risks associated with customer concentration [18][19].

星标 ★ IPO日报 精彩文章第一时间推送 五次闯关A股未果，最终选择了前往港交所，赌一个上市可能。 这就是近日申请在港交所主板上市的口腔材料公司Huge Dental Limited（下称"沪鸽"）。 作为医疗服务行业俗语"金眼银牙铜骨头"中"银牙"产业链上游的知名公司，沪鸽为何屡屡登不上A股的舞台？是沪鸽的竞争力不 强吗？ 最早，沪鸽于2015年4月在新三板挂牌，后在2017年6月摘牌。 从2017年开始，沪鸽和招商证券签署辅导协议，开启了辅导之路，拟申请创业板上市，直到2019年1月以双方终止协议为终点。 2019年底，沪鸽和海通证券签署辅导协议，谋求科创板上市。然而不到一年，沪鸽和海通证券分道扬镳，转身和中原证券"牵 手"，希望奔向上市的幸福彼岸。 2021年12月，沪鸽申请创业板IPO受理，接受一轮问询，随后又于2022年8月申请终止上市。 2022年9月，沪鸽上市辅导再次进行了备案，辅导机构为中原证券，随后则因撤回辅导备案而终止。 2023年8月，沪鸽再次备案开启上市辅导，辅导机构为国金证券，最终未有成果。 制图：佘诗婕 四任保荐机构，五次备案，历经六年 港交所官网披露，沪鸽已递表港交所，申请主板 ...